Results 221 to 230 of about 16,598,865 (356)

Editorial: Affecting, emoting, and feeling disability: entanglements at the intersection of disability studies and the sociology of emotions

Frontiers in Sociology
Yvonne Wechuli, Marie Sépulchre, Kelly Fritsch   +2 more
doaj   +1 more source

Effectiveness of clinical healthcare interventions for enhancing the work participation of patients with various health conditions: a synthesis of systematic reviews. [PDF]

BMJ Open
Kluit L, Hoving JL, Jamaludin FS, van Bennekom CAM, Beumer A, de Boer AGEM, de Wind A.   +6 more
europepmc   +1 more source

Views of breast cancer survivors on work participation guidance by general practitioners: a qualitative study. [PDF]

BMC Prim Care, 2022
Sarfo MC, van Asselt KM, Frings-Dresen MH, de Jong F, van Dijk N, de Boer AGEM.   +5 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Effectiveness and Characteristics of Work Participation Interventions for Adults with Musculoskeletal Upper Limb Conditions: A Systematic Review. [PDF]

J Occup Rehabil
Newington L, Ceh D, Sandford F, Parsons V, Madan I.   +4 more
europepmc   +1 more source

Work participation is reduced during the development of RA, months before clinical arthritis manifests. [PDF]

Rheumatology (Oxford), 2022
Rogier C, de Jong PHP, van der Helm-van Mil AHM, van Mulligen E.   +3 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Trends in work participation among patients with inflammatory rheumatic musculoskeletal diseases (iRMDs): Data from the German National Database (2010-2022). [PDF]

RMD Open
Veltri C, Albrecht K, Kiltz U, Meyer-Olson D, Späthling S, Strangfeld A, Thiele K, Callhoff J.   +7 more
europepmc   +1 more source

Worker role perceptions and work participation among people with mental health issues taking part in interventions focusing on everyday life. [PDF]

Work, 2023
Eklund M, Bäckström M.
europepmc   +1 more source

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source